Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
On Tuesday, the US Food and Drug Administration (FDA) approved Amgen’s RANK-L inhibitor denosumab (Prolia®) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. However, what they have not done (yet) … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: denosunam, fracture, Prevention, Prolia | Leave a Comment »
According to a report from Reuters and a media release on the Amgen web site, the European Medicines Agency (EMEA) has approved denosumab (Prolia®) for marketing in Europe. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, Prolia | 2 Comments »
According to a company media release issued last Friday, Amgen has filed a second new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval of denosumab (a RANK-L inhibitor to be known commercially as Prolia®). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: Amgen, approval, denosumab, FDA, Prolia | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site